Optimizing the correlation between results of testing in vitro and therapeutic outcome in vivo for fluconazole by testing critical isolates in a murine model of invasive candidiasis

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 1, 1998, Pages 129-134

  Rex, John H ^a,d   Nelson, Page W ^a   Paetznick, Victor L ^a   Lozano Chiu, Mario ^a   Espinel Ingroff, A ^b   Anaissie, Elias J ^c  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA ALBICANS; CANDIDA TROPICALIS; CANDIDIASIS; CONTROLLED STUDY; DRUG SENSITIVITY; FUNGUS GROWTH; IN VITRO STUDY; IN VIVO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031982890     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.1.129     Document Type: Article

References (22)

1. Anaissie, E., V. Paetznick, and G. P. Bodey. 991. Fluconazole susceptibility testing of Candida albicans: microtiter method that is independent of inoculum size, temperature, and time of reading. Antimicrob. Agents Chemother. 25:1641-1646.
2. Anaissie, E. J., N. C. Karyotakis, R. Hachem, M. C. Dignani, J. H. Rex, and V. Paetznick. 1994. Correlation between in vitro and in vivo activity of antifungal agents against Candida species. J. Infect. Dis. 170:384-389.
3. Barry, A. L., and S. D. Brown. 1996. Fluconazole disk diffusion procedure for determining susceptibility of Candida species. J. Clin. Microbiol. 34:2154-2157.
4. Belander, P., C. C. Nast, R. Frati, H. Sanati, and M. Ghannoum. 1997. Voriconazole (UK-109,496) inhibits the growth and alters the morphology of fluconazole-susceptible and -resistant Candida species. Antimicrob. Agents Chemother. 41:1840-1842.
5. Borgers, M., and M.-A. Van de Ven. 1987. Degenerative changes in fungi after itraconazole treatment. Rev. Infect. Dis. 9:(Suppl. 1):S33-S42.
6. Espinel-Ingroff, A., C. W. Kish, T. M. Kerkering, R. A. Fromtling, K. Bartizal, J. N. Galgiani, K. Villareal, M. A. Pfaller, T. Gerarden, M. G. Rinaldi, and A. Fothergill. 1992. Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests. J. Clin. Microbiol. 30:3138-3145.
7. Espinel-Ingroff, A., A. Quart, L. Steele-Moore, I. Metcheva, G. A. Buck, V. L. Bruzzese, and D. Reich. 1996. Molecular karyotyping of multiple yeast species isolates from nine patients with AIDS during prolonged fluconazole therapy. J. Med. Vet. Mycol. 34:111-116.
8. Espinel-Ingroff, A., L. Steele-Moore, and J. N. Galgiani. 1994. Evaluation of 80% inhibition standards for the determination of fluconazole minimum inhibitory concentrations in three laboratories. Diagn. Microbiol. Infect. Dis. 20:81-86.
9. Fromtling, R. A., J. N. Galgiani, M. A. Pfaller, A. Espinel-Ingroff, K. F. Bartizal, M. S. Bartlett, B. A. Body, C. Frey, G. Hall, G. D. Roberts, F. B. Nolte, F. C. Odds, M. G. Rinaldi, A. M. Sugar, and K. Villareal. 1993. Multicenter evaluation of a broth macrodilution antifungal susceptibility test for yeasts. Antimicrob. Agents Chemother. 37:39-45.
10. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11. Pfaller, M. A., M. Bale, B. Buschelman, M. Lancaster, A. Espinel-Ingroff, J. H. Rex, M. G. Rinaldi, C. R. Cooper, and M. R. McGinnis. 1995. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of amphotericin B, fluconazole, and flucytosine. J. Clin. Microbiol. 33:1104-1107.
12. Pfaller, M. A., J. H. Rex, and M. G. Rinaldi. 1997. Antifungal susceptibility testing: technical advances and potential clinical applications. Clin. Infect. Dis. 24:776-784.
13. Pfaller, M. A., J. Rhine-Chalberg, A. L. Barry, J. H. Rex, NIAID Mycoses Study Group, and the Candidemia Study Group. 1995. Strain variation and antifungal susceptibility among bloodstream isolates of Candida species from 21 different medical institutions. Clin. Infect. Dis. 21:1507-1509.
14. Rex, J. H., J. E. Bennett, A. M. Sugar, P. G. Pappas, C. M. Van der Horst, J. E. Edwards, R. G. Washburn, W. M. Scheld, A. W. Karchmer, A. P. Dine, M. J. Levenstein, C. D. Webb, the Candidemia Study Group, and the NIAID Mycoses Study Group. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N. Engl. J. Med. 331:1325-1330.
15. Rex, J. H., C. R. Cooper, Jr., W. G. Merz, J. N. Galgiani, and E. J. Anaissie. 1995. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob. Agents Chemother. 39:906-909.
16. Rex, J. H., P. W. Nelson, M. Lozano-Chiu, V. L. Paetznick, and E. J. Anaissie. 1996. Fluconazole MICs for Candida are more predictive of outcome in vivo when read after 24 hours rather than 48 hours, abstr. 74. In 34th Annual Meeting of the Infectious Diseases Society of America, New Orleans.
17. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannoum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, A. L. Barry, and Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
18. Rex, J. H., M. A. Pfaller, M. Lancaster, F. C. Odds, A. Bolmström, and M. G. Rinaldi. 1996. Quality control guidelines for National Committee for Clinical Laboratory Standards recommended broth macrodilution testing of ketoconazole and itraconazole. J. Clin. Microbiol. 34:816-917.
19. Rex, J. H., M. A. Pfaller, M. G. Rinaldi, A. Polak, and J. N. Galgiani. 1993. Antifungal susceptibility testing. Clin. Microbiol. Rev. 6:367-381.
20. Rodriguez-Tudela, J. L., and J. V. Martinez-Suarez. 1994. Improved medium for fluconazole susceptibility testing of Candida albicans. Antimicrob. Agents Chemother. 38:45-48.
21. Tornatore, M. A., G. A. Noskin, D. M. Hacek, A. A. Obias, and L. R. Peterson. 1997. Effects of incubation time and buffer concentration on in vitro activities of antifungal agents against Candida albicans. J. Clin. Microbiol. 35:1473-1476.
22. Wanger, A., K. Mills, P. W. Nelson, and J. H. Rex. 1995. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates. Antimicrob. Agents Chemother. 39:2520-2522.